MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?

Almuntashiri, Sultan; Zhang, Duo; Somanath, Payaningal R; Sikora, Andrea

Almuntashiri, Sultan; Zhang, Duo; Somanath, Payaningal R; Sikora, Andrea.

Affiliation

Almuntashiri S; Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, 30912, USA.
Zhang D; Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, 30912, USA.
Somanath PR; Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, 30912, USA.
Sikora A; Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA, 30912, USA.

Infect Disord Drug Targets ; 23(1): e190622206159, 2023.

Article in En | MEDLINE | ID: mdl-35726419

Subject(s)

COVID-19; Respiratory Distress Syndrome; Humans; Matrix Metalloproteinase 3/therapeutic use; Respiratory Distress Syndrome/diagnosis; Respiratory Distress Syndrome/drug therapy; COVID-19 Drug Treatment; Biomarkers

Key words

ARDS; Biomarker; MMP3; potential pharmacological target; respiratory failure; therapeutic target

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Infect Disord Drug Targets Journal subject: DOENCAS TRANSMISSIVEIS / TERAPIA POR MEDICAMENTOS Year: 2023 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google